Assessing frailty in older Indian patients before cancer treatment: Comparative analysis of three scales and their implications for overall survival
Abhijith R Rao,Vanita Noronha,Anant Ramaswamy,Anita Kumar,Anupa Pillai,Shreya Gattani,Arshiya Sehgal,Sharath Kumar,Renita Castelino,Jessica Pearce,Ratan Dhekale,Pravin Jagtap,Vinod Tripathi,Sunita Satamkar,Jyoti Krishnamurthy,Sarika Mahajan,Anuradha Daptardar,Lekhika Sonkusare,Jayita Deodhar,Nabila Ansari,Manjusha Vagal,Purabi Mahajan,Shivshankar Timmanpyati,Manjunath Nookala,Ankita Chitre,Akhil Kapoor,Vikram Gota,Shripad Banavali,Rajendra A Badwe,Kumar Prabhash,Abhijith R. Rao,Rajendra A. Badwe
DOI: https://doi.org/10.1016/j.jgo.2024.101736
IF: 3.929
2024-04-01
Journal of Geriatric Oncology
Abstract:INTRODUCTION: Frailty, characterized by ageing-related vulnerability, influences outcomes in older adults. Our study aimed to investigate the relationship between frailty and clinical outcomes in older Indian patients with cancer.MATERIALS AND METHODS: Our observational single-centre study, conducted at Tata Memorial Hospital from February 2020 to July 2022, enrolled participants aged 60 years and above with cancer. Frailty was assessed using the Clinical Frailty Scale (CFS), G8, and Vulnerable Elders Survey (VES)-13. The primary objective was to explore the correlation between baseline frailty and overall survival. Statistical analyses include Kaplan-Meier, Cox proportional hazards, and Harrell's C test.RESULTS: A total of 1,177 patients (median age 68, 76.9% male) were evaluated in the geriatric oncology clinic. Common malignancies included lung (40.0%), gastrointestinal (35.8%), urological (11.9%), and head and neck (9.0%), with 56.5% having metastatic disease. Using CFS, G8, and VES-13 scales, 28.5%, 86.4%, and 38.0% were identified as frail, respectively. Median follow-up was 11.6 months, with 43.3% deaths. Patients fit on CFS (CFS 1-2) had a median survival of 28.02 months, pre-frail (CFS 3-4) 13.24 months, and frail (CFS ≥5) 7.79 months (p < 0.001). Abnormal G8 (≤14) and VES-13 (≥3) were associated with significantly lower median survival (p < 0.001). Multivariate analysis confirmed CFS's predictive power for mortality (p < 0.001), with hazard ratios [HRs] for pre-frail at 1.61(95% confidence interval [CI] 1.25 to 2.06) and frail at 2.31 (95%CI 1.74 to 3.05). G8 ≤ 14 had HR 2.00 (95%CI 1.42 to 2.83), and abnormal VES-13 had HR 1.36 (95%CI 1.11-1.67). In the likelihood ratio test, CFS significantly improved the model fit (p < 0.001). Harrell's C index for survival prediction was 0.62 for CFS, 0.54 for G8, and 0.58 for VES-13.DISCUSSION: In conclusion, our study highlights varying frailty prevalence and prognostic implications in older Indian patients with cancer, emphasizing the need for personalized care in oncology for this aging population. We would recommend using CFS as a tool to screen for frailty for older Indian patients with cancer.
oncology,geriatrics & gerontology,gerontology